BACKGROUND:ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF). We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF. METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to eitherexercise training or usual care. ST2 was analyzed in a subset of 910 patients with evaluable plasma samples. Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes. The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8). ST2 was modestly associated with measures of functional capacity. In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL). In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide. However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement. CONCLUSIONS:ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk. CLINICAL TRIAL INFORMATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.
RCT Entities:
BACKGROUND:ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF). We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF. METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care. ST2 was analyzed in a subset of 910 patients with evaluable plasma samples. Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes. The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8). ST2 was modestly associated with measures of functional capacity. In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL). In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide. However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement. CONCLUSIONS:ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk. CLINICAL TRIAL INFORMATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.
Authors: Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2010-12-22 Impact factor: 8.790
Authors: Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray Journal: J Am Coll Cardiol Date: 2010-01-19 Impact factor: 24.094
Authors: Inder S Anand; Tibor Kempf; Thomas S Rector; Heike Tapken; Tim Allhoff; Franziska Jantzen; Michael Kuskowski; Jay N Cohn; Helmut Drexler; Kai C Wollert Journal: Circulation Date: 2010-09-20 Impact factor: 29.690
Authors: Domingo A Pascual-Figal; Jordi Ordoñez-Llanos; Pedro L Tornel; Rafael Vázquez; Teresa Puig; Mariano Valdés; Juan Cinca; Antoni Bayes de Luna; Antoni Bayes-Genis Journal: J Am Coll Cardiol Date: 2009-12-01 Impact factor: 24.094
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee Journal: Circulation Date: 2008-03-31 Impact factor: 29.690
Authors: Kenjiro Seki; Shoji Sanada; Anastacia Y Kudinova; Matthew L Steinhauser; Vandna Handa; Joseph Gannon; Richard T Lee Journal: Circ Heart Fail Date: 2009-09-22 Impact factor: 8.790
Authors: Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker Journal: JACC Heart Fail Date: 2017-10 Impact factor: 12.035
Authors: Panagiotis Savvoulidis; James V Snider; Sahil Rawal; Alanna A Morris; Javed Butler; Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos Journal: Int J Cardiol Date: 2019-11-06 Impact factor: 4.164
Authors: Tariq Ahmad; Emily C O'Brien; Phillip J Schulte; Susanna R Stevens; Mona Fiuzat; Dalane W Kitzman; Kirkwood F Adams; William E Kraus; Ileana L Piña; Mark P Donahue; Faiez Zannad; David J Whellan; Christopher M O'Connor; G Michael Felker Journal: Circ Heart Fail Date: 2015-06-01 Impact factor: 8.790
Authors: Hicham Skali; Robert Gerwien; Timothy E Meyer; James V Snider; Scott D Solomon; Craig M Stolen Journal: J Cardiovasc Transl Res Date: 2016-10-31 Impact factor: 4.132
Authors: Christopher S Lee; Quin E Denfeld; Bradley E Aouizerat; Corrine Y Jurgens; Christopher V Chien; Emily Aarons; Jill M Gelow; Shirin O Hiatt; James O Mudd Journal: Heart Lung Date: 2018-10-09 Impact factor: 2.210